The estimated Net Worth of Capital Partners Iii, Llc L... is at least $9.62 Milion dollars as of 31 January 2022. Capital L owns over 175,000 units of Sierra Oncology Inc stock worth over $9,623,250 and over the last 3 years Capital sold SRRA stock worth over $0.
Capital has made over 1 trades of the Sierra Oncology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Capital bought 175,000 units of SRRA stock worth $4,725,000 on 31 January 2022.
The largest trade Capital's ever made was buying 175,000 units of Sierra Oncology Inc stock on 31 January 2022 worth over $4,725,000. On average, Capital trades about 87,500 units every 0 days since 2022. As of 31 January 2022 Capital still owns at least 175,000 units of Sierra Oncology Inc stock.
You can see the complete history of Capital L stock trades at the bottom of the page.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth a James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: